SDGR

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Bill GatesGates Foundation Trust $79M7M shares TrimQ1 2026 $46M $11.36 $13.24

News

fool.comRecursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?fool.comJun 2

gurufocus.comA Look at Schrodinger Inc (SDGR) After 6.9% Gain -- GF Value $26.55 vs Price $14.15gurufocus.comMay 28

businesswire.comSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)businesswire.comMay 22

fool.comMy Top 3 Biotech Stocks for May 2026fool.comMay 20

247wallst.com7 Healthcare AI Stocks Under $50 With Huge Upside Potential247wallst.comMay 18

Trade SDGR

About Schrödinger, Inc.

Schrödinger, Inc., along with its affiliated entities, specializes in developing and deploying a sophisticated, physics-based software platform designed to accelerate the discovery of novel molecules. This technology finds application in both pharmaceutical development and various materials science endeavors. The company's operations are divided into two primary segments: Software and Drug Discovery. Within its Software division, Schrödinger focuses on marketing and licensing its specialized software. This software primarily serves drug discovery efforts within the life sciences industry, but also caters to clients in materials science sectors. Conversely, the Drug Discovery segment is dedicated to cultivating a portfolio of both preclinical and clinical programs. These initiatives are pursued both through internal research and development and via strategic collaborations. Schrödinger's global clientele spans biopharmaceutical companies, industrial enterprises, academic institutions, and government research laboratories worldwide. Founded in 1990, the company maintains its headquarters in New York, New York.

CEO: Ramy Farid
IPO Date: Feb 6, 2020

Market Data

Open: $14.23
High: $15.04
Low: $14.09
Volume: 928K
52W High: $27.63
52W Low: $10.95

Valuation

Market Cap: $1.1B
Enterprise Value: $932M

Financials

Free Cash Flow: $12M
Revenue: $256M
Net Income: $-103M
Cash: $231M
Debt: $109M

Events

EarningsAug 5

EPS est. -0.6